Acorda Therapeutics Inc ACOR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:41 AM EDT
4.53quote price arrow down-0.20 (-4.23%)
Volume
48,008
52 week range
2.53 - 9.84

...

Loading . . .
  • Open4.75
  • Day High4.75
  • Day Low4.50
  • Prev Close4.73
  • 52 Week High9.84
  • 52 Week High Date10/20/20
  • 52 Week Low2.53
  • 52 Week Low Date09/14/20

Key Stats

  • Market Cap42.99M
  • Shares Out9.49M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change8.68

KEY STATS

  • Open4.75
  • Day High4.75
  • Day Low4.50
  • Prev Close4.73
  • 52 Week High9.84
  • 52 Week High Date10/20/20
  • 52 Week Low2.53
  • 52 Week Low Date09/14/20
  • Market Cap42.99M
  • Shares Out9.49M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change8.68

RATIOS/PROFITABILITY

  • EPS (TTM)-12.53
  • P/E (TTM)-0.36
  • Fwd P/E (NTM)-0.60
  • EBITDA (MRQ)25.248M
  • ROE (MRQ)-36.30%
  • Revenue (MRQ)152.97M
  • Gross Margin (MRQ)78.09%
  • Net Margin (MRQ)-65.11%
  • Debt To Equity (MRQ)98.68%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Acorda Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also...
John Kelley
Non-Executive Chairman
Ron Cohen M.D.
Chief Executive Officer
Robert Morales
Chief Financial Officer
Address
420 Saw Mill River Rd
Ardsley, NY
10502-2605
United States

Top Peers

SYMBOLLASTCHG%CHG
ATNX
Athenex Inc
4.04+0.03+0.75%
SURF
Surface Oncology Inc
6.79+0.16+2.44%
HBIO
Harvard Bioscience Inc
6.67+0.16+2.46%
CLVS
Clovis Oncology Inc
6.07-0.01-0.25%
CPRX
Catalyst Pharmaceuticals Inc
4.70+0.10+2.07%